Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

Developed by international researchers led by British experts, RI-AG03, tackles two 'hotspots' on the protein that leads to ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...

According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in Japan for treating early symptomatic Alzheimer’s disease ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

The 829 registered participants from 156 teams in Sunday's Walk to End Alzheimer's Northern Virginia, held at Reston Town ...

An array of pharmaceutical pills with the company's logo on the bottle. According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in ...

The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges it will ...